195 related articles for article (PubMed ID: 22893598)
1. A novel approach to the discovery of small-molecule ligands of CDK2.
Martin MP; Alam R; Betzi S; Ingles DJ; Zhu JY; Schönbrunn E
Chembiochem; 2012 Sep; 13(14):2128-36. PubMed ID: 22893598
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potential allosteric ligand binding site in CDK2.
Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
[TBL] [Abstract][Full Text] [Related]
3. Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.
Faber EB; Tian D; Burban D; Levinson NM; Hawkinson JE; Georg GI
ACS Chem Biol; 2020 Jul; 15(7):1759-1764. PubMed ID: 32433863
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
5. Probing an Allosteric Pocket of CDK2 with Small Molecules.
Christodoulou MS; Caporuscio F; Restelli V; Carlino L; Cannazza G; Costanzi E; Citti C; Lo Presti L; Pisani P; Battistutta R; Broggini M; Passarella D; Rastelli G
ChemMedChem; 2017 Jan; 12(1):33-41. PubMed ID: 27860401
[TBL] [Abstract][Full Text] [Related]
6. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
7. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery.
Craven GB; Affron DP; Allen CE; Matthies S; Greener JG; Morgan RML; Tate EW; Armstrong A; Mann DJ
Angew Chem Int Ed Engl; 2018 May; 57(19):5257-5261. PubMed ID: 29480525
[TBL] [Abstract][Full Text] [Related]
9. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
10. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
[TBL] [Abstract][Full Text] [Related]
11. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
12. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
13. The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.
García-Sosa AT; Mancera RL
J Mol Model; 2006 Mar; 12(4):422-31. PubMed ID: 16374623
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel nonpeptide allosteric inhibitors interrupting the interaction of CDK2/cyclin A3 by virtual screening and bioassays.
Hu Y; Li S; Liu F; Geng L; Shu X; Zhang J
Bioorg Med Chem Lett; 2015 Oct; 25(19):4069-73. PubMed ID: 26316466
[TBL] [Abstract][Full Text] [Related]
15. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
[TBL] [Abstract][Full Text] [Related]
16. The rise of fragment-based drug discovery.
Murray CW; Rees DC
Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
[TBL] [Abstract][Full Text] [Related]
18. CSBB-ConeExclusion, adapting structure based solution virtual screening to libraries on solid support.
Shave S; Auer M
J Chem Inf Model; 2013 Dec; 53(12):3156-62. PubMed ID: 24266324
[TBL] [Abstract][Full Text] [Related]
19. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Cyclin A2 Binding Site and Nanomolar Inhibitors of Cyclin A2-CDK2 Complex.
Kim SS; Alves MJ; Gygli P; Otero J; Lindert S
Curr Comput Aided Drug Des; 2021; 17(1):57-68. PubMed ID: 31889491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
